Update: Phase IIb trial of APC activator underway
Prima BioMed has initiated a Phase IIb study of IMP321 in metastatic breast cancer, marking the start of a period of expected strong newsflow from its in-house and partnered LAG-3 programmes in cancer and autoimmune diseases. The trial represents the return to the clinic of IMP321, a soluble LAG-3 fusion protein that doubled the tumour response rate vs chemo alone in Phase IIa, which was acquired with the other LAG-3 programmes with the purchase of Immutep in late 2014. The proceeds of the recent capital raise increase our valuation to A$273m (vs A$271m).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.